SCHEMBL3672344

SCHEMBL3672344

O=C(Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3C3CC3)cc12)c1ccoc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 19/20 0.77
ROCK2 O75116 5/20 0.61
PRKACA P17612 5/20 0.61
CDK2 P24941 5/20 0.61
MAP4K4 O95819 4/20 0.61
PIM1 P11309 4/20 0.61
HIPK2 Q9H2X6 4/20 0.61
MKNK2 Q9HBH9 3/20 0.61
GSK3B P49841 2/20 0.61
CLK4 Q9HAZ1 2/20 0.61
DAPK3 O43293 5/20 0.53
CDK5 Q00535 5/20 0.53
DYRK1A Q13627 5/20 0.53
CLK2 P49760 4/20 0.53
PRKX P51817 4/20 0.53
STK17A Q9UEE5 4/20 0.53
MAP4K5 Q9Y4K4 4/20 0.53
AURKA O14965 3/20 0.53
MAPK13 O15264 3/20 0.53
PRKCG P05129 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3669567 0.91 CDC7 (0.88) CDC7ROCK2PRKACACDK2MAP4K4
SCHEMBL3667572 0.88 CDC7 (0.85) CDC7ROCK2PRKACACDK2MAP4K4
SCHEMBL3675478 0.88 CDC7 (0.75) CDC7ROCK2PRKACACDK2MAP4K4
SCHEMBL3667172 0.87 CDC7 (1.00) CDC7ROCK2PRKACACDK2MAP4K4
SCHEMBL3673419 0.86 CDC7 (1.00) CDC7ROCK2PRKACACDK2MAP4K4
SCHEMBL28787693 0.85 CDC7 (0.76) CDC7ROCK2PRKACACDK2MAP4K4
SCHEMBL3673674 0.85 CDC7 (0.78) CDC7ROCK2PRKACACDK2MAP4K4
SCHEMBL3670732 0.85 CDC7 (0.84) CDC7ROCK2PRKACACDK2MAP4K4
SCHEMBL3667584 0.84 CDC7 (0.73) CDC7ROCK2PRKACACDK2MAP4K4
SCHEMBL3671100 0.83 CDC7 (0.78) CDC7ROCK2PRKACACDK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885PRKACA 178/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885PRKACA 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.